What Is BPC-157? Mechanism of Action & Research Applications

TL;DR: BPC-157 (Body Protection Compound 157, sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a synthetic 15-amino acid pentadecapeptide derived from a fragment of human gastric juice BPC protein. It has no identified high-affinity receptor; proposed mechanisms involve modulation of nitric oxide (NO) synthesis, VEGF-driven angiogenesis, and growth factor receptor signaling. Its research interest stems from observed cytoprotective and tissue-repair effects in rodent models.

What Is BPC-157?

BPC-157 (also designated PL 14736) is a 15-amino acid peptide fragment (pentadecapeptide) isolated from the partial sequence of human Body Protection Compound (BPC), a protein found in gastric juice. The peptide sequence is: H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH.

The molecular weight of BPC-157 is 1419.54 Da, and its CAS number is 137525-51-0. It is a water-soluble peptide, relatively stable in plasma compared to many short peptides, and does not require fatty acid conjugation for in vitro stability over standard experimental timescales. The compound is most commonly supplied as a lyophilized acetate salt.

Unlike the GLP-1 analogues in this catalog, BPC-157 does not act through a well-characterized single receptor. Its research interest is therefore driven primarily by functional readouts in in vitro and in vivo models rather than receptor occupancy assays, which makes rigorous assay controls especially important when designing BPC-157 studies.

Proposed Mechanisms of Action

BPC-157 does not have a confirmed primary receptor target as of the current research literature. Multiple downstream mechanisms have been proposed and investigated in in vitro and in vivo models.

Nitric Oxide System Modulation

Several studies report that BPC-157 effects are attenuated by NOS inhibitors (L-NAME) and abolished in eNOS-deficient mice, suggesting that endothelial nitric oxide synthase (eNOS) activation is a component of its mechanism. Proposed signaling involves BPC-157 interaction with the NO-cGMP axis to promote vasodilation and endothelial cytoprotection. Researchers designing BPC-157 studies should include NOS inhibitor controls to assess NO-dependence of observed endpoints.

VEGF and Angiogenesis

BPC-157 has been shown to upregulate vascular endothelial growth factor (VEGF) and its receptor VEGFR2 (KDR/Flk-1) in several wound-healing and ischemia models. The proposed angiogenic mechanism involves BPC-157-driven endothelial proliferation and tube formation in Matrigel assays — a readout reproducible in human umbilical vein endothelial cell (HUVEC) culture. This VEGF-angiogenesis axis is the most commonly cited mechanism in tissue repair research using BPC-157.

Growth Factor Receptor Transactivation

Some evidence from gastric mucosal cell and fibroblast studies suggests BPC-157 can activate EGFR and FAK-paxillin pathways associated with cell migration and survival. In tendon and ligament fibroblast cultures, BPC-157 treatment has been associated with increased collagen synthesis and cell viability under oxidative stress conditions.

Gastrointestinal Cytoprotection

BPC-157’s origin from gastric juice corresponds to its most extensively studied activity — cytoprotection of gastric mucosa. In gastric epithelial cell lines and rodent ulcer models, BPC-157 attenuates ethanol- and NSAID-induced mucosal injury. Proposed mechanisms include prostaglandin-independent cytoprotection, mucus secretion promotion, and suppression of oxidative mucosal damage.

Important note for researchers: Because no primary receptor has been confirmed for BPC-157, mechanistic claims should be interpreted with caution. Studies using knockout models, selective pathway inhibitors, and appropriate vehicle controls are necessary for attributing observed effects to specific molecular mechanisms.

BPC-157 Research Applications

BPC-157 is primarily used in preclinical research investigating tissue repair, gastrointestinal mucosal biology, and vascular biology — areas where its angiogenic and cytoprotective properties in model systems make it a useful experimental tool.

For procurement details, see the bulk BPC-157 product page.

BPC-157 vs. Growth Factor–Based Repair Research Tools

In tissue repair and angiogenesis research, BPC-157 is frequently compared with or used alongside direct growth factor peptides such as VEGF(165), EGF, and FGF-2. The key distinction is mechanistic: growth factors bind known, well-characterized receptors with defined downstream signaling cascades, while BPC-157 acts upstream through less-defined modulatory pathways.

VEGF(165) directly binds VEGFR2 (KDR/Flk-1) with picomolar affinity and drives a well-mapped RTK/ERK/AKT angiogenic cascade. BPC-157, by contrast, upregulates endogenous VEGF and VEGFR2 expression rather than substituting for the ligand — positioning it as an endogenous pathway modulator rather than a receptor agonist. This distinction is experimentally meaningful: VEGF controls isolate receptor-level effects, while BPC-157 experiments reveal upstream regulatory biology.

In gastrointestinal cytoprotection research, BPC-157 is sometimes compared with misoprostol (a prostaglandin E1 analogue). Misoprostol protects gastric mucosa through EP receptor activation and prostaglandin-dependent pathways. Studies showing that BPC-157’s cytoprotective effect persists after indomethacin treatment (which blocks prostaglandin synthesis) suggest its GI protection mechanism is prostaglandin-independent — making it useful for studies where prostaglandin pathway confounds need to be avoided.

For connective tissue and tendon repair studies, BPC-157 is often used alongside or compared with platelet-derived growth factor (PDGF-BB) and transforming growth factor beta (TGF-β1). PDGF-BB and TGF-β1 activate defined RTK and serine/threonine kinase receptors with well-characterized collagen synthesis and fibroblast proliferation readouts. BPC-157’s FAK-paxillin pathway activation in fibroblasts suggests it may engage cytoskeletal reorganization and integrin signaling — a complementary, non-overlapping mechanism that justifies its use as an orthogonal comparison arm in tendon repair assays.

Because BPC-157’s mechanism remains partially uncharacterized, researchers designing comparative studies should include both positive controls (selective growth factor receptor agonists) and pathway-specific inhibitors to parse BPC-157’s contributions from endogenous growth factor signaling.

Key Takeaways

  1. BPC-157 is a 15-amino acid synthetic pentadecapeptide fragment derived from human gastric juice protein BPC (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val).
  2. No confirmed primary receptor has been identified; proposed mechanisms involve eNOS/NO signaling, VEGF-driven angiogenesis, and growth factor receptor transactivation.
  3. Research applications center on endothelial angiogenesis (HUVEC tube formation), GI mucosal cytoprotection, and connective tissue biology.
  4. Because no primary receptor is established, studies require NOS inhibitor controls, VEGF pathway blockers, and robust vehicle controls to attribute effects to specific mechanisms.
  5. The compound is water-soluble, does not require albumin-binding modifications, and is suitable for standard cell culture media reconstitution at physiologically relevant concentrations.

Buy Bulk BPC-157 → · CJC-1295 Research Guide · Ipamorelin Research Guide · All Research Guides · Full Bulk Peptides Catalog

Published by Bulk Peptides, a US-based wholesale supplier of research-grade peptides. All products are for in vitro laboratory research use only (RUO) — not for human or veterinary use. Last reviewed August 2026.